Posted On: 08 Oct 2025
HaemaLogiX Ltd, a clinical stage Australian biotech company developing novel immunotherapies for patients with blood cancers (HaemaLogiX), provides the following personnel update.
Executive team changes
Damian Clarke-Bruce has elected to step down from the role of CEO and Managing Director of HaemaLogiX to pursue other opportunities. As a result, Dr Geoff Nichol, who has served on the HaemaLogiX Board as Non-Executive Director since July 2022 and is the Chair of the Science and Technology Committee has agreed to step into the role of Executive Director and Chief Operating Officer of HaemaLogiX, effective 1 November 2025.
Damian Clarke-Bruce said: “It has been a privilege to work with the HaemaLogiX team as the company progressed its mission of advancing new immunotherapies for patients with multiple myeloma and B cell disorders. I look forward to seeing these treatments reach those patients who need them most.”
Dr Geoff Nichol, Executive Director and Chief Operating Officer, commented: “In an extension of my current role as Chair of the HaemaLogiX Science and Technology Committee, I look forward to working even more closely with the highly committed HaemaLogiX team to advance our clinical and pre-clinical programs and progress our planned IPO. The novel KMA and LMA targets at HaemaLogiX have the potential to transform treatment for patients with multiple myeloma due to their exquisite specificity for cancer cells, that may limit negative impacts on the immune system seen with current therapies.”
In parallel with Dr Nichol stepping in as Executive Director, the Board has commenced an executive search process for a new CEO and Managing Director. An update on the outcomes of that process will be provided in due course.
Board changes
Prof the Hon Greg Hunt has also advised that he wishes to step down as Non-Executive Director at this time so that he can concentrate on other obligations and interests which are expected to take up more of his time, particularly in the context of HaemaLogiX's progress towards its planned IPO.
Prof The Hon Greg Hunt, said: “It has been a privilege to work with such a talented group of people, however given both my academic, philanthropic and other roles it is important to ensure there is appropriate time to do justice to each. I am more optimistic than ever about the prospects for HaemaLogiX helping patients with multiple myeloma and look forward to the next round of clinical trial results with belief and enthusiasm.”
HaemaLogiX will continue to progress the planned phase 2b KappaMab clinical trial and phase 1 KMA.CAR T cell clinical trials that are currently underway. These management and Board changes are not expected to impact the Company’s clinical and preclinical development strategies.
John Cullity, Executive Chairman of HaemaLogiX, said: “On behalf of the Board, I would like to recognise Damian for his efforts, dedication and commitment during his time with HaemaLogiX. The Board also sincerely thanks Greg for his many valuable contributions. We wish them both all the best in their future endeavours.”
We are delighted that Dr Geoff Nichol will take on an executive role with HaemaLogiX. Geoff has an exceptional pedigree in drug development, in particular in antibody development. His strategic and clinical expertise will be invaluable as we progress our next clinical trials for our KappaMab and KMA.CAR-T cell immunotherapies.”